Anemia in Patients with CVD and CKD: Current Management and Potential Role of HIF-PHIs (webcourse)

Format: Webcourse

Credit(s): 1.00 (60 min)

Release Date: Nov 16, 2022

Expiration Date: Nov 16, 2023

Credit Type(s):

MIPS Improvement Activity Under MACRA
Physicians – AMA PRA Category 1 Credit(s) ™
Physicians/ABIM MOC – ABIM MOC Point(s)

PROGRAM OVERVIEW

Anemia in CKD is associated with poor CV outcomes, increased risk of CKD progression, decreased health-related quality of life (HRQOL), and increased healthcare resource utilization. Erythropoiesis-stimulating agents have been the standard of care for treating anemia in CKD but are associated with CV safety concerns; other therapies include red blood cell transfusions and iron administration but each potentially has severe adverse events.

Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are promising novel agents in development for treating CKD-associated anemia. These oral agents increase endogenous erythropoietin production, improve iron absorption and mobilization, and decrease hepcidin production in the liver.

Anemia in Patients with CVD and CKD: Current Management and Potential Role of HIF-PHIs will provide cardiologists with information about the etiology of anemia in CKD, the effects on CV disease, HRQOL, and function, advantages and limitations of current management strategies, and the efficacy and safety data for HIF-PHIs in late-stage development for the management of CKD-related anemia.